Are GLP-1s a Miracle, a Mistake, or Something More Complicated?
GLP-1s are everywhere. What's real, what's hype, and what aren't we talking about?
Prefer to listen to a human conversation?
She came in carrying a printed list of questions. She had PCOS, prediabetes, high cholesterol. She’d struggled with her weight since puberty, developed an eating disorder in middle school, and had spent years seeing doctors who told her, in one form or another, to lose weight. The most recent one had said it within the first five minutes of meeting her — before any labs were reviewed, before her history was taken — and had recommended a GLP-1.
She wasn’t sure she wanted it. She’d seen it all over social media — the before-and-afters and the warnings. She’d seen celebrities who suddenly looked completely different, and she’d seen people online saying that GLP-1s were destroying people’s relationships with food. She didn’t know who to believe.
This is a story we hear almost every week, in some variation. And it’s the story that made us want to do this episode.
Because GLP-1 medications are genuinely, legitimately revolutionary — and also genuinely complicated in ways that the current conversation doesn’t always make room for.
The Claim
If you’ve spent any time on social media in the last few years, you’ve encountered at least one of these narratives. GLP-1s are a miracle drug that will end obesity and metabolic disease as we know it. Or: GLP-1s are dangerous and full of scary side effects that your doctor isn’t telling you about. Or: people who use them are lazy, cheating, and setting themselves up for lifelong dependence on a pharmaceutical company. Or: GLP-1s are deepening fat phobia and will cause a wave of eating disorders. Or, maybe most cynically: doctors who prescribe them are bought by Big Pharma.
None of these framings is quite right. And most of them leave out the thing that actually matters: context.
Why It’s Going Viral
These drugs came of age during a very particular cultural moment. Semaglutide (Wegovy) was approved in 2021 — peak COVID, peak social media usage, peak collective health anxiety. At the same time, direct-to-consumer drug marketing was evolving rapidly from generic TV commercials into influencer marketing, where real people who had used these medications were being paid to talk about their results to audiences who trusted and felt connected to them. That’s a fundamentally different kind of persuasion.
Then came the celebrity photographs. People who had publicly struggled with their weight for years suddenly looked dramatically different. And a medication that had been quietly used for diabetes management became a cultural phenomenon almost overnight.
The result was enormous demand, significant drug shortages, a boom in compounding pharmacies, asynchronous telehealth platforms offering prescriptions without any real clinical relationship, and a lot of very strong opinions being formed on very incomplete information.
Meanwhile, for people who have spent years feeling dismissed by a healthcare system that told them to simply eat less and move more — or who have metabolic conditions that diet and exercise alone couldn’t adequately address — the appeal of an effective medication is not irrational. It’s completely understandable. And that’s exactly why this conversation matters.
What the Science Shows
Let’s start with what these medications actually are. GLP-1 stands for glucagon-like peptide-1, and GLP-1 receptor agonists have been around since 2005 — long before Wegovy became a household name. They work by slowing gastric emptying, reducing glucose levels by increasing insulin and decreasing glucagon, and acting on brain regions associated with appetite and reward. Some newer formulations, like tirzepatide (Mounjaro/Zepbound), also target a second receptor called GIP, giving them dual action.
The benefits, for the right patients, are real and well-documented.
For people with type 2 diabetes, these medications have been genuinely transformative — offering improvements in blood sugar control that were not possible with older drugs. For high-risk patients with existing cardiovascular disease or diabetes, a meta-analysis of nearly 100,000 patients found significant reductions in all-cause mortality, cardiovascular mortality, and major adverse cardiovascular events. There are also documented benefits for chronic kidney disease in people with diabetes, and for metabolic-associated fatty liver disease (previously called non-alcoholic fatty liver disease). A 2025 meta-analysis of 25 randomized controlled trials found meaningful improvements in liver inflammation and liver fat, with tirzepatide showing particularly robust effects.
Weight loss, in large trials, ranges from about 6% with some formulations to nearly 18–25% with newer agents. But weight loss as a standalone “benefit” warrants careful framing. The critical caveat is sustainability. A 2025 study from Vanderbilt University found that weight cycling — the lose-regain-lose pattern that many patients experience — was associated with a nearly 30% increased risk for conditions like sleep apnea, fatty liver disease, and type 2 diabetes, and a more than 50% increased risk of heart failure, compared to weight stability at any body size. This means the question isn’t just whether a medication causes weight loss. It’s whether that weight loss can be sustained — and what happens if it isn’t.
The risks are also real. GI side effects (nausea, diarrhea, constipation, vomiting) are the most common and are usually dose-dependent and time-limited, though not trivial. Gallbladder events, including gallstones, are increased by about 26%. Loss of lean muscle mass and bone density are meaningful concerns, particularly at higher doses — though research suggests exercise can significantly mitigate both. The thyroid cancer signal, which carries a black-box warning, appears primarily relevant to people with specific rare genetic conditions (MEN2), and the biological plausibility for risk in humans is generally considered low. A 2024 study found that GLP-1 use was actually associated with reduced overall cancer incidence across most obesity-associated cancer types, though a possible signal for kidney cancer warrants further study.
The mental health picture is more nuanced. Initial pharmacovigilance data raised concerns about depression and suicidality, but subsequent meta-analyses did not show a statistically significant direct drug effect — pointing instead to the underlying psychiatric burden in populations who are already navigating weight stigma, weight cycling, and inadequate care. However, signals for eating disorder-related adverse events with all three major GLP-1 medications have not been similarly resolved. This is particularly important given that many people who might be candidates for these medications have a history of disordered eating, whether recognized or not.
Clinical Nuance
The biggest clinical risk in the current moment is extrapolation: applying the findings of a cardiovascular outcomes trial in people with existing heart disease to someone who is otherwise metabolically healthy but wants to lose weight. The populations are not the same, and the risk-benefit calculation is not the same.
Thoughtful prescribing means starting with the question: what are we actually treating? If there is a diagnosable metabolic condition — diabetes, fatty liver disease, sleep apnea, cardiovascular disease — the data is more straightforward. If the primary indication is weight loss in an otherwise healthy person just because of their BMI (a metric known to be flawed and not designed to be used to define an individual person’s health), the conversation needs to be much more careful and individualized, including a frank discussion of what stopping the medication might mean long-term.
It also means screening for disordered eating before prescribing. Most primary care providers have never received formal training in eating disorder screening, and the rates of disordered eating in this population are high. Brief, validated tools like the SCOFF or the Eating Disorder Screen for Primary Care (ESP) can be administered quickly in clinical practice. What you find should shape whether, how, and at what dose you proceed.
There is also a real concern about access and equity. These medications are expensive — $149–499 per month out of pocket, and increasingly being dropped from insurance coverage. When patients can’t sustain access, they stop. And stopping, without a plan, is a clinical event. Compounded formulations present additional safety concerns: variable sourcing, inadequate regulation, salt forms that are not pharmacologically identical to the approved drugs, and, in some cases, outright fraud. The FDA has documented counterfeit compounded products listing pharmacies that don’t exist. This is the environment in which many patients are obtaining these medications.
Finally, it is worth sitting with the societal dimension of this moment. These medications have, in some corners of the internet, been framed as eliminating any excuse for a larger body size. That framing is harmful. It amplifies weight stigma. It ignores the complexity of why people’s bodies are the sizes they are. And it can make already-vulnerable patients feel that their choices about their own bodies are being made for them by cultural pressure rather than genuine clinical partnership.
The Antidote
For Patients
(Gentle reminders and affirmations)
Wanting an effective treatment for a metabolic health condition is not weakness. It is reasonable.
Using a medication does not mean you failed at lifestyle change. It means you have a condition that may benefit from medical treatment.
You deserve a full conversation about what this medication can do, what it cannot do, and what the plan is if circumstances change.
You also deserve to be asked about your relationship with food before anyone prescribes you something that changes appetite and reward pathways.
Feeling uncertain or conflicted about this is appropriate. This is genuinely complicated, and you are allowed to take your time.
Weight stigma is real, and its effects on your health and your care are also real. You deserve a clinician who sees that.
For Clinicians
(Language you can borrow, tweak, or make your own)
“I want to make sure we talk about what this medication can and can’t do — and what it would mean to be on it long-term.”
“Before we go further, I’d love to ask a few questions about your history with food and eating. Not to judge anything, but because it actually changes how I think about the right approach for you.”
“The cardiovascular benefits we hear about are real, but they’re strongest in people who already have heart disease or diabetes. Let’s talk about where you actually fit in that picture.”
“If cost or access becomes an issue down the road, I want us to have a plan. Stopping without a plan is a clinical risk, and I want to think through that with you now.”
“This medication works best as part of a broader picture — including nutrition support, movement you actually enjoy, and monitoring for how it’s affecting you.”
“Our goal isn’t a number on the scale. Our goal is your metabolic health and your quality of life, and I want to keep checking in on both.”
Sources and Further Reading
Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of 99,599 Patients. JACC, 2025. https://www.jacc.org/doi/10.1016/j.jacc.2025.08.027
Cardiovascular and Kidney Outcomes and Mortality with Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes. Diabetes Care, 2025. https://diabetesjournals.org/care/article-abstract/48/5/846/158048
Efficacy of GLP-1-based Therapies on Metabolic Dysfunction-associated Steatotic Liver Disease and Steatohepatitis: A Systematic Review and Meta-analysis. J Clin Endocrinol Metab, 2025. https://pubmed.ncbi.nlm.nih.gov/40489581/
Efficacy and Safety of GLP-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes. Annals of Internal Medicine, 2025. https://pubmed.ncbi.nlm.nih.gov/39761578/
Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM, 2021. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
Tirzepatide for Adults Living with Obesity. Cochrane / PubMed, 2025. https://pubmed.ncbi.nlm.nih.gov/41161687/
Weight Trajectory Impacts Risk for 10 Distinct Cardiometabolic Diseases. J Clin Endocrinol Metab, 2025. https://pubmed.ncbi.nlm.nih.gov/40498904/
Nutritional Priorities to Support GLP-1 Therapy for Obesity: A Joint Advisory. American Journal of Clinical Nutrition, 2025. https://ajcn.nutrition.org/article/S0002-9165(25)00240-0/fulltext
Bone Health After Exercise Alone, GLP-1 Receptor Agonist Treatment, or Combination Treatment. JAMA Network Open. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2820308
GLP-1RA Use and Thyroid Cancer Risk. JAMA Otolaryngology, 2024. https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/2829462
GLP-1 Receptor Agonists and Cancer Risk in Adults with Obesity. JAMA Oncology, 2024. https://jamanetwork.com/journals/jamaoncology/article-abstract/2837870
Suicide and Self-Harm Events With GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis. JAMA Psychiatry, 2024. https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2831637
Psychiatric and Psychological Adverse Effects Associated with Dulaglutide, Semaglutide, and Liraglutide: A VigiBase Study. Clinical Nutrition, 2025. https://pubmed.ncbi.nlm.nih.gov/40617160/
GLP-1 Receptor Agonists and Research to Treat Overeating and Substance Use Disorders. PubMed, 2025. https://pubmed.ncbi.nlm.nih.gov/41224657/
FDA: Concerns About Unapproved GLP-1 Drugs Used for Weight Loss. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
Medical Students for Size Inclusivity. GLP-1 Agonist Medications: Informed Consent Resource. 2023. https://sizeinclusivemedicine.org/glp1/